Our Patent Litigation team is a proud partner to the world’s most innovative life sciences and technology companies. Our experience successfully handling high-stakes patent matters, joined with Paul, Weiss's legendary litigation capabilities, enable us to provide comprehensive strategies to protect our clients’ most valuable innovations that extend well beyond traditional patent litigation.
Intellectual Property Litigation: Federal Circuit May Decide Prior Art Estoppel Issue
March 15, 2019 Download PDF
Litigation partner Lew Clayton’s latest intellectual property litigation column, “Federal Circuit May Decide Art Estoppel Issue,” appeared in the March 13 issue of the New York Law Journal. The authors discuss BTG Int’l Ltd. v. Amneal Pharm., in which the Federal Circuit may decide whether §315(e)(2) acts to bar a successful inter partes review petitioner from asserting in district court the arguments that prevailed before the Patent Trial and Appeal Board. Litigation associates Michael Milea and Saurabh Gupta assisted in the preparation of this article.